The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

There are currently no FDA-approved treatments for FAP, a condition characterized by the proliferation of polyps in the colon and/or rectum.

The FDA has granted rare paediatric disease and orphan drug designations for IN013, Innorna's mRNA therapeutic for Wilson's ...